All In Biotech

NDA 021196 · Jazz Pharms

Xyrem

Sodium Oxybate · Oral

NovelPriority reviewOrphan

Last checked: Nov 19, 2026Latest source record: Jul 28, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2002

Jul 17, 2002

Approved uses

5

Original approval plus efficacy supplements

Registered trials

59

17 Phase 3, 4 recruiting

FAERS reports

62,191

32,274 serious, 941 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: CENTRAL NERVOUS SYSTEM DEPRESSION and ABUSE AND MISUSE. • Central Nervous System Depression Xyrem (sodium oxybate) is a CNS depressant. In clinical trials at recommended doses, obtundation and clinically significant respiratory depression occurred in adult patients treated with Xyrem [see Warnings and Precautions ( 5.1 )]. Many patients who received Xyrem during clinical trials in narcolepsy were receiving central nervous system stimulants [see Clinical Trials ( 14 )]. • Abuse and Misuse Xyrem ® (sodium oxybate) is the sodium salt of gamma-hydroxybutyrate (GHB). Abuse or misuse of illicit GHB, either alone or in combination with other CNS depressants, is associated with CNS adverse reactions, including seizure, respiratory depression, decreases in the level of consciousness, coma, and death [see Warnings and Precautions ( 5.2 )]. Because of the risks of CNS depression and abuse...

What it is approved for

From the label in effect Jul 1, 2025.

Xyrem is indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy. Xyrem is a central nervous system depressant indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy ( 1 ).

Mechanism: Xyrem is a CNS depressant. The mechanism of action of Xyrem in the treatment of narcolepsy is unknown. Sodium oxybate is the sodium salt of gamma-hydroxybutyrate (GHB), an endogenous compound and metabolite of the neurotransmitter GABA. It is hypothesized that the therapeutic effects of Xyrem on cataplexy and excessive daytime sleepiness are mediated through GABA B actions at noradrenergic and dopaminergic neurons, as well as at thalamocortical neurons.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • XYREM · SODIUM OXYBATE 0.5GM/ML · SOLUTION, ORAL · Prescription · TE AA

Clinical trials

Interventional ClinicalTrials.gov studies with "Oxybate" as an intervention, any sponsor and status, largest first.

All 59 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • nausea4,303
  • anxiety3,664
  • somnolence3,187
  • depression3,032
  • headache2,931
  • feeling abnormal2,899
  • condition aggravated2,798
  • weight decreased2,785
  • fatigue2,672
  • dizziness2,640
  • insomnia2,567
  • sleep apnoea syndrome2,550

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200445
200530
200653
2007102
2008138
2009217
2010328
2011533
2012909
2013921
20141,831
201511,443
201619,535
20175,544
20184,530
20193,963
20203,142
20212,958
20222,041
20231,876
20241,124
2025508
2026420

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Xyrem (Sodium Oxybate)

2024 spending

$70.3M

Beneficiaries

534

3,735 claims

Per beneficiary

$131,559

$39.27 per unit

View as table
YearSpending
2020$287,143,624
2021$208,290,136
2022$156,545,926
2023$98,471,849
2024$70,252,475

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 131 on PubMed

Sponsor: Jazz Pharmaceuticals

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.